Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
5.725
Zitationen
14
Autoren
2007
Jahr
Abstract
Progression-free survival was longer and response rates were higher in patients with metastatic renal-cell cancer who received sunitinib than in those receiving interferon alfa (ClinicalTrials.gov numbers, NCT00098657 and NCT00083889 [ClinicalTrials.gov]).
Ähnliche Arbeiten
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
2017 · 15.274 Zit.
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
2013 · 6.560 Zit.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
2015 · 5.839 Zit.
Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma
2007 · 4.772 Zit.
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
2018 · 4.535 Zit.
Autoren
Institutionen
- Memorial Sloan Kettering Cancer Center(US)
- Texas Oncology(US)
- Centrum Onkologii(PL)
- Massachusetts General Hospital(US)
- Cleveland Clinic(US)
- Sorbonne Université(FR)
- Pitié-Salpêtrière Hospital(FR)
- Hôpital Européen(FR)
- Hôpital Européen Georges-Pompidou(FR)
- Centre Léon Bérard(FR)
- Wojskowy Instytut Medycyny Lotniczej(PL)
- Pfizer (United States)(US)
- City of Hope(US)